https://oncbrain.oncologytoolkit.com/ AI-summarized oncology meeting studies, curated by a subspecialist. One item per study. en Sat, 30 May 2026 00:00:00 GMT https://oncbrain.oncologytoolkit.com/2026-05-30/#prepec https://oncbrain.oncologytoolkit.com/2026-05-30/#prepec Sat, 30 May 2026 00:00:00 GMT breast [Confirmatory] BREAST-Q chest score 79.2 vs 74.3 (diff 4.8, p=0.01) favoring pre-pectoral IBBR; implant loss 21% vs 15%. Eligible: Nipple-sparing or skin-sparing mastectomy for breast cancer treatment or risk re https://oncbrain.oncologytoolkit.com/2026-05-27/#senomac https://oncbrain.oncologytoolkit.com/2026-05-27/#senomac Wed, 27 May 2026 00:00:00 GMT breast [Confirmatory] 5yr RFS 89.7% vs 88.7%, HR 0.89: SNB alone noninferior to ALND in cN0 breast cancer with 1-2 SN macrometastases. Eligible: cN0 breast cancer, T1-T3, 1-2 SN macrometastases, BCT or mastectomy https://oncbrain.oncologytoolkit.com/2026-05-19/#eplnd-psma-pet-prostate-staging https://oncbrain.oncologytoolkit.com/2026-05-19/#eplnd-psma-pet-prostate-staging Tue, 19 May 2026 00:00:00 GMT prostate [Challenges SOC] 47.7% of LN mets outside ePLND template; PSMA PET NPV ~96%; RCTs no consistent BCR benefit from routine dissection. Eligible: Localized prostate cancer, intermediate to high risk, primary staging pre-RP